Warnings and Precautions Gallbladder abnormalities may occur. There have been postmarketing reports of cholelithiasis (gallstones) resulting in complications, including cholecystitis, cholangitis, ...
Sandostatin® LAR Depot (octreotide acetate) for injectable suspension for treatment of the severe diarrhea and flushing associated with metastatic carcinoid tumors
Sandostatin LAR Depot has been designed to target somatostatin receptors.1,2
Sandostatin LAR Depot inhibits hormone secretions
Sandostatin LAR Depot provides somatostatin receptor–targeted inhibition
Octreotide binds to somatostatin receptors that are highly expressed on the surface of carcinoid tumors, where it inhibits the release of gastrin, vasoactive intestinal peptide, secretin, motilin, and serotonin1-3,6
5-HIAA, 5-hydroxyindoleacetic acid.
References: 1. Sandostatin LAR Depot [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2019. 2. Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol. 2006;17(12):1733-1742. 3. Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999;17(2):600-606. 4. Öberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004;15(6):966-973. 5. Davis Z, Moertel CG, McIlrath DC. The malignant carcinoid syndrome. Surg Gynecol Obstet. 1973;137:637-644. 6. Chaudhri O, Small C, Bloom S. Gastrointestinal hormones regulating appetite. Philos Trans R Soc Lond B Biol Sci. 2006;361(1471):1187-1209.
IMPORTANT SAFETY INFORMATION
Warnings and Precautions
Please see full Prescribing Information.
Indications and Usage
Sandostatin® LAR Depot (octreotide acetate) for injectable suspension is indicated for patients in whom initial treatment with immediate-release Sandostatin® (octreotide acetate) Injection has been shown to be effective and tolerated for
In patients with carcinoid syndrome and VIPomas, the effect of Sandostatin Injection and Sandostatin LAR Depot on tumor size, rate of growth, and development of metastases has not been determined.